Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Reexamination Certificate
2006-10-03
2006-10-03
Tsang, Cecilia J. (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
C546S133000, C514S529000, C514S507000
Reexamination Certificate
active
07115768
ABSTRACT:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
REFERENCES:
patent: 4085057 (1978-04-01), Masuda et al.
patent: 4438122 (1984-03-01), Holmwood et al.
patent: 4505910 (1985-03-01), Bagli
patent: 4518600 (1985-05-01), Holmwood et al.
patent: 4544402 (1985-10-01), Schnurbusch et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4672065 (1987-06-01), Spatz
patent: 4908368 (1990-03-01), Murase et al.
patent: 4959364 (1990-09-01), Mueller et al.
patent: 4992439 (1991-02-01), Meanwell
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5120734 (1992-06-01), Klausener et al.
patent: 5238934 (1993-08-01), Knuppel et al.
patent: 5278184 (1994-01-01), Artico et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5580868 (1996-12-01), Lunkenheimer et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5814643 (1998-09-01), Duggan et al.
patent: 5821231 (1998-10-01), Arrhenius et al.
patent: 5861429 (1999-01-01), Sato et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5942504 (1999-08-01), Grobelny
patent: 5955491 (1999-09-01), Sohda et al.
patent: 5962479 (1999-10-01), Chen
patent: 5972946 (1999-10-01), Murata et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 6465513 (2002-10-01), Grant et al.
patent: 0 330 506 (1989-08-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 99/64390 (1999-02-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/52898 (1999-10-01), None
patent: WO 00/43354 (2000-07-01), None
Zhou et al, Yingyoung Huaxue (1999) 16 (4) pp. 6 to 9.
Abraham, W.M., et al. “α4-Integrins Mediate Antigen -induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep.”J. Clin. Invest. 93:776-787 (1994).
Bao, L., et al. “Correlation of VLA-4 integrin expression with metastatic potential in various human tumour cell lines.”Diff. 52: 239-246 (1993).
Baron, J.L., et al. “Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma.”J. Exp. Med. 177: 57-68 (1993).
Baron, J.L., et al. et al. “The Pathogenesis of Adeoptive Murine Autonimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1.”J. Clin. Invest. 93: 1700-1708 (1994).
Burkly, L.C., et al. “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigent-4 Integrin.”Diabetes. 43: 529-534 (1994).
Cybulsky, M.I., et al. “Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis,”Science. 251: 788-791 (1991).
Elices, M.J., et al. “Expression and Functional Significance of Alternatively Spliced CS1 Fibronecting in Rheumatoid Arthritis Microvasculature..”J. Clin. Invest. 93: 405-416 (1994).
Elices, M.J., et al. “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the CLA-4/Fibronectin Binding Site.”Cell. 60: 577-584 (1990).
Hamann, A., et al. “Role of α4-Integrins in Lymphocute Homing to Mucosal Tissues in Vivo.”J. Immunology. 152:3283-3292 (1994).
Hladon, B., et al. In Vitro cytostatic activity of some amino acid 4-N-substituted cytosines.Arch. Immunol. Ther. Exp. 40(2): 145-150 (1992). (Abstract).
Hoffman, S., et al. “N-Pyrimidinylamino acids. III. N-(oxopyrimidinyl) derivatives of neutral amino acids.”Z. Chem. 12(1): 21-22 (1972), CODEN: ZECEAL (Abstract).
Kawaguchi, S., et al. “VLA-4 Molecules on Tumor Cells Initiate an Adhesive Interaction with VCAM-1 Molecules on Endothelial Cell Surface.”Japanese J. Cancer Res. 83: 1304-1316 (1992).
Lauri, D., et al. “Decreased adhesion to endothelial cells and matrix proteins of H-2Kbgene transfected tumour cells.”British J. Cancer. 68: 862-867 (1993).
Li, H., et al. “An Atherogenic Diet Rapidly Induces VCAM-1, a Cytokine-Regulatable Mononuclear Leeukocyte Adhesion Molecule, in Rabbit Aortic Endothelium.”Arterioscler. Thromb. 13(2): 197-204 (1993).
Mulligan, M.S., et al. “Role of β1, β2 Integrins and ICAM-1 in Lung Injury after Deposition of IgG and IgA Immune Complexes.”J. Immunol. 150(6): 2407-2417 (1993).
Okarhara, H., et al. “Involvement of Very Late Activation Antigen 4 (VLA-4) and Vascular Cell Adhesion Molecule 1(VCAM-1) in Tumor Necrosis Factor α Enhancement of Experimental Metastasis.”Can. Res. 54: 3233-3236 (1994).
Osborn, L. “Leukocyte Adhesion to Endothelium in Inflammation.”Cell. 62: 3-6 (1990).
Paavonen, T., et al. “In VivoEvidence of the Role of α4β1-VCAM-1 Interaction in Sarcoma, but not in Carcinoma Extravasation.”Int. J. Can. 58:298-302 (1994).
Paul, L.C.,et al. “Monoclonal Antibodies Against LFA-1 and VLA-4 Inhibit Graft Vasculitis in Rat Cardiac Allografts.”Transpl. Proceed. 25(1): 813-814 (1993).
Postigo, A.A., et al. “Increased Binding of Synovial T Lumphocytes from Rheumatoid Arthritis to Endothelial-Leukocyte Adhesion Molecule-1 (ELAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1).”J. Clin. Invest. 89: 1445-1452 (1991).
Pretolani, M., et al. “Antibody to Very Late Activation Antigen 4 Prevents Antigen-induced Bronchial Hyperractivity and Cellular Infiltration in the Guinea Pig Airways.”J. Exp. Med. 180: 795-805 (1994).
Sasseville, V.G., et al. “Monocyte Adhesion to Endothelium in Simian Immunodeficiency Virus-Induced Aids Encephalitis is Mediated by Vascular Cell Adhesion Molecule-1/α4β1Integrin Interactions.”Am. J. Path. 144(1): 27-40 (1994).
Schadendorf, D., et al. “Tumour Progression and Metastatic BehaviourIn VivoCorrelates with Integrin Expression on Melanocytic Tumours.”J. Path. 170: 429-434 (1993).
Springer, T.A. “Adhesion receptors of the immune system.”Nature. 346: 425-434 (1990).
Teranishi, K., et al. “Synthesis and Chemiluminescence of Coelenterazine (OplophorusLuciferin) Analogues.”Bull. Chem. Soc. Jpn. 63(11): 3132-3140 (1990).
Van Dinther-Janssen, A.C.H.M., et al. “Role of the CS1 adhesion motif of fibronectin in T cell adhesion to synovial membrane and peripheral lymph node endothelium.”Annals. Rheumatic Dis. 52: 672-676 (1993).
Van Dinther-Janssen, A.C.H.M., et al. “The VLA-4/VCAM-1 Pathway is Involved in Lymphocyte Adhesion to Endothelium in Rheumatoid Synovium.”J. Immunology. 147(12): 4207-4210 (1991).
Vedder, N.B., et al. “Role of neutrophils in generalized reperfusion injury associated with resuscitation from shock.”Surgery. 106: 509-516 (1989).
Yang, C-D., et al. “Inhibition of insultitis and prevention of diabetes in nonobese diabetic mice by blocking L-selecting and very late antigen 4 adhesion receptors.”Proc. Natl. Acad. Sci., USA. 90: 10494-10498 (1993).
Yednock, T.A., et al. “Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1integrin.”Nature. 356: 63-66 (1992).
Grant Francine S.
Johnson Bradley S.
Pleiss Michael A.
Thorsett Eugene D.
Elan Pharmaceuticals Inc.
Foley & Lardner LLP
Reyes Hector M
Tsang Cecilia J.
LandOfFree
Multicyclic compounds which inhibit leukocyte adhesion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multicyclic compounds which inhibit leukocyte adhesion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multicyclic compounds which inhibit leukocyte adhesion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3644538